Form 4: Corcept Therapeutics President Exercises Options and Sells Shares Under Pre-Arranged Plan

Corcept Therapeutics' President of Endocrinology, Sean Maduck, executed a series of transactions including the exercise of stock options, acquisition of shares through a purchase plan and restricted stock awards, and the sale of common stock, all under a pre-arranged 10b5-1 trading plan.

Summary

• Sean Maduck, President of Corcept Endocrinology at Corcept Therapeutics Inc. (CORT), engaged in multiple transactions on June 2, 2025.
• He acquired 888 shares of common stock at a price of $71.68 per share through a purchase plan established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan.
• An additional 888 shares were acquired as unvested restricted stock awards under the Purchase Plan, with a price of $0, which will vest on the one-year anniversary of the grant date.
• Mr. Maduck exercised stock options to acquire 20,000 shares of common stock at an exercise price of $5.05 per share.
• Concurrently, he disposed of a total of 20,000 shares of common stock through multiple sales transactions, all executed pursuant to a Rule 10b5-1 plan adopted on September 5, 2024.
• The sales occurred at weighted average prices ranging from $77.9101 to $80.7669 per share, with actual sale prices ranging from $77.56 to $81.00.
• Following these transactions, Mr. Maduck directly beneficially owns 17,705 shares of common stock and 61,986 stock options.
• Indirectly, he beneficially owns 89,693 shares through the Sean and Molly Maduck Living Trust and 10,000 shares through Duckhill Capital, LLC.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there was a significant sale of shares, it was executed under a pre-planned 10b5-1 arrangement, which mitigates negative interpretations. The executive also acquired shares through a purchase plan and restricted stock awards, and exercised options, indicating continued engagement and a mix of transactions.

Positives

• The acquisition of 888 shares through a purchase plan and 888 shares as restricted stock awards indicates continued investment and alignment with company performance.
• The exercise of 20,000 stock options at a strike price of $5.05 suggests that the current market price of Corcept Therapeutics common stock is significantly higher, indicating a profitable exercise for the insider and potential confidence in the stock's value.

Negatives

• Sean Maduck sold a total of 20,000 shares of common stock, which could be perceived as a reduction in direct insider exposure, although these sales were pre-planned under a 10b5-1 plan.

Future Outlook

NA

Industry Context

This Form 4 filing details routine insider transactions for an executive at a biotechnology company. Such filings are common and provide transparency into executive stock ownership and trading activities, which are often pre-scheduled through 10b5-1 plans to avoid accusations of trading on material non-public information.

Related Party Transactions

• Shares are held indirectly through the Sean and Molly Maduck Living Trust, of which the Reporting Person is a co-trustee.
• Shares are held indirectly through Duckhill Capital, LLC, of which the Reporting Person is President, though he disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders may observe a decrease in direct insider ownership due to the sales, though the pre-planned nature of these transactions (10b5-1 plan) suggests they are not a reaction to new negative information.
• The exercise of options and acquisition of new shares through a purchase plan and restricted stock awards demonstrate continued alignment of management interests with shareholders, as the executive maintains a substantial beneficial ownership position.

Next Steps

• The unvested restricted stock awards granted on September 3, 2024, December 2, 2024, and March 3, 2025, are expected to vest on their respective one-year anniversaries, provided certain requirements are met.
• The unvested restricted stock awards acquired under the Purchase Plan are expected to vest on the one-year anniversary of the grant date, provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such anniversary.

Key Dates

Recommendation

Keywords

Corcept Therapeutics, CORT, Insider Trading, Form 4, Stock Options, Restricted Stock Units, 10b5-1 Plan, Sean Maduck, Executive Compensation, Biotechnology, Pharmaceuticals